Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors

Acta Paediatrica, International Journal of Paediatrics

Volumn 94, Issue 6, 2005, Pages 672-677

  Aldámiz Echevarría, Luis ^a,b   Pocheville, Itziar ^a   Sanjurjo, Pablo ^a   Elorz, Javier ^a   Prieto, Jose Angel ^a   Rodríguez Soriano, Juan ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

Fatty acid composition; HIV infected children; Insulin resistance; Protease inhibition

Indexed keywords

ACYL COENZYME A DESATURASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FATTY ACID; GLUCOSE; LINOLEOYL COENZYME A DESATURASE; LONG CHAIN FATTY ACID; MONOUNSATURATED FATTY ACID; NELFINAVIR; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYUNSATURATED FATTY ACID; PROTEINASE INHIBITOR; RITONAVIR; SOMATOMEDIN C; TRIACYLGLYCEROL;

ARTICLE; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID COMPOSITION; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

CHILD; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FATTY ACIDS; FATTY ACIDS, UNSATURATED; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; NELFINAVIR; RITONAVIR; TRIGLYCERIDES;

EID: 20544467243     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250510028362     Document Type: Article

References (30)

1. Jaquet D, Lèvine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123-8.
2. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo controlled study. AIDS 2002;16:F1-8.
3. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV associated cardiovascular complications. Lancet Infec Dis 2001;1:115-24.
4. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003;14:15-9.
5. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, et al. AHA Scientific Statement. Cardiovascular health in childhood. Circulation 2002;106:143-60.
6. Hernández M, Castellet J, Narvaiza JL, Rincón JM, Ruiz E, Sánchez E, et al. Curvas y tablas de crecimiento. Madrid: Garsi; 1988.
7. Estellés A, Dalmau J, Falcó C, Berbel O, Castelló R, España F, et al. Plasma PAI-1 levels in obese children. Effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001;138:485-92.
8. Gungor N, Saad R, Janosky J, Arslanian S. Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 2004;144:47-55.
9. Lepage G, Roy CC. Direct transesterification of all classes of lipids in one step reaction. J Lip Res 1986;27:114-20.
10. Riddle TM, Schildmeyer NM, Phan CP, Fichtenbaum CJ, Hui DY. The HIV protease inhibitor increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res 2002;43:1458-63.
11. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21:405-10.
12. Tran H, Robinson S, Mikhailenko I, Strickland DK. Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res 2003;44:1859-69.
13. Petit JM, Duong M, Duvillard L, Florentin E, Portier H, Lizard G, et al. LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy. Eur J Clin Invest 2002;32:354-9.
14. Ranganathan S, Kern PA. The HIV pro tease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J Endocrinol 2002;172:155-62.
15. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall H. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of "systemic steatosis". Curr Opin Lipidol 2004;15:59-67.
16. Festa A, D'Agostino R, Tracy RP, Haffner SM. The Insulin Resistance Atherosclerosis Study. Elevated levels of acute phase proteins and plasminogen activator inhibitor 1 predict the development of type 2 diabetes. Diabetes 2002;51: 1131-7.
17. Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 2003; 23:688-94.
18. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1 infected patients treated with protease inhibitor containing highly active antiretroviral therapy. Acquir Immune Defic Syndr 2002;15:441-9.
19. Herz J, Strickland DK. LRP: a multifunctional scavenger and signalling receptor. J Clin Invest 2001;108:779-84.
20. Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70 year old men. Diabetologia 1994;43: 1353-7.
21. Pelikanova T, Kazdova L, Chvojkova S, Base J. Serum phospholipid fatty acid composition and insulin action in type 2 diabetic patients. Metabolism 2001;50:1472-8.
22. Bitnun A, Sochett E, Babyn P, Holowa S, Stephens D, Read S, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003;17: 1319-27.
23. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, et al. Liver specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50:1110-8.
24. Sutinen J, Silveira A, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, Yki-Jarvinen H. Circulating concentrations of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003;88:1907-10.
25. Xu A, Yin S, Wong L, Chan KW, Lam KSL. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor rotanavir in mice. Endocrinology 2004;145:487-94.
26. Rondanelli M, Caselli D, Arico M, Maccabruni A, Magnani B, Bachella L, et al. Insulin-like growth factor I (IGF-1) and IGF-binding protein 3 response to growth hormone is impaired in HIV-infected children. AIDS Res Hum Retroviruses 2002; 20:331-9.
27. Viganò A, Mora S, Brambilla P, Schenider L, Merlo M, Monti LD, et al. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS 2003;17:1435-41.
28. Ferdinadusse S, Denis S, Mooijer PAW, Zhang Z, Reddy JK, Spector AA, et al. Identification of the peroxisomal β-oxidation enzymes involved in the biosynthesis of docosahexaenoic acid. J Lipid Res 2001;42:1987-95.
29. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV 1 infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026-31.
30. Matsuzaka T, Shimano H, Yahagi N, Amemiya-Kudo M, Yoshikawa T, Hasty AH, et al. Dual regulation of mouse Δ5 and Δ6 desaturase gene expression by SREBP-1 and PPARα. J Lipid Res 2002;43:107-14.